Under the joint research collaboration agreement, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs. The parties may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.
Maryland Biomanufacturing Leaders Discuss Challenges, Future Needs at 2020 Bio Innovation Conference
The BioHealth Capital Region (BHCR) is known globally as a leading vaccine hub with nearly 20% of the world’s leading vaccine development influencers in Maryland, which is the heart of the BHCR.
Former MedImmune Employees Leading In the BioHealth Capital Region and Beyond In a recent conversation someone shared the quote “You can’t throw a stone in the BioHealth Capital Region and [….]
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer Rockville, MD, June 16, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based [….]
BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological [….]
These Five Capital Region Biotechs Are The Fastest Growing in America December 5, 2018 In its 24th year, the Deloitte Technology Fast 500 is the premier technology awards program in [….]